LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
MedPage Today on MSN
Gene Therapy-Induced CAR T Cells for Myeloma Could Alter Treatment Landscape
ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...
An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...
Natera's PALLAS study data show MRD status strongly predicts five-year recurrence risk in stage II–III HR+/HER2- breast ...
A conditioning regimen free from total body irradiation (TBI) appeared to be just as effective as standard of care (SoC) in a ...
Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...
Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation ...
Please provide your email address to receive an email when new articles are posted on . Those who sustained MRD negativity for more than 6 months achieved longer response duration and PFS. All ...
News-Medical.Net on MSN
Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...
During the 2025 American Society of Hematology annual meeting, held earlier this month in Orlando, Florida, CURE sat down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback